Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Sirolimus for non-progressive NF1-associated plexiform neurofibromas: an NF clinical trials consortium phase II study.

Weiss B, Widemann BC, Wolters P, Dombi E, Vinks AA, Cantor A, Korf B, Perentesis J, Gutmann DH, Schorry E, Packer R, Fisher MJ.

Pediatr Blood Cancer. 2014 Jun;61(6):982-6.

PMID:
24851266
2.

Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study.

Weiss B, Widemann BC, Wolters P, Dombi E, Vinks A, Cantor A, Perentesis J, Schorry E, Ullrich N, Gutmann DH, Tonsgard J, Viskochil D, Korf B, Packer RJ, Fisher MJ.

Neuro Oncol. 2015 Apr;17(4):596-603. doi: 10.1093/neuonc/nou235. Epub 2014 Oct 14. Erratum in: Neuro Oncol. 2015 Jun;17(6):905.

3.

Sirolimus improves pain in NF1 patients with severe plexiform neurofibromas.

Hua C, Zehou O, Ducassou S, Minard-Colin V, Hamel-Teillac D, Wolkenstein P, Valeyrie-Allanore L.

Pediatrics. 2014 Jun;133(6):e1792-7. doi: 10.1542/peds.2013-1224.

4.

Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas.

Kim A, Gillespie A, Dombi E, Goodwin A, Goodspeed W, Fox E, Balis FM, Widemann BC.

Neurology. 2009 Oct 20;73(16):1273-9. doi: 10.1212/WNL.0b013e3181bd1326.

5.

Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.

Widemann BC, Babovic-Vuksanovic D, Dombi E, Wolters PL, Goldman S, Martin S, Goodwin A, Goodspeed W, Kieran MW, Cohen B, Blaney SM, King A, Solomon J, Patronas N, Balis FM, Fox E, Steinberg SM, Packer RJ.

Pediatr Blood Cancer. 2014 Sep;61(9):1598-602. doi: 10.1002/pbc.25041. Epub 2014 Apr 22.

PMID:
24753394
6.

Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.

Widemann BC, Dombi E, Gillespie A, Wolters PL, Belasco J, Goldman S, Korf BR, Solomon J, Martin S, Salzer W, Fox E, Patronas N, Kieran MW, Perentesis JP, Reddy A, Wright JJ, Kim A, Steinberg SM, Balis FM.

Neuro Oncol. 2014 May;16(5):707-18. doi: 10.1093/neuonc/nou004. Epub 2014 Feb 4.

7.

Preclincial testing of sorafenib and RAD001 in the Nf(flox/flox) ;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging.

Wu J, Dombi E, Jousma E, Scott Dunn R, Lindquist D, Schnell BM, Kim MO, Kim A, Widemann BC, Cripe TP, Ratner N.

Pediatr Blood Cancer. 2012 Feb;58(2):173-80. doi: 10.1002/pbc.23015. Epub 2011 Feb 11.

8.

Clinic-based study of plexiform neurofibromas in neurofibromatosis 1.

Waggoner DJ, Towbin J, Gottesman G, Gutmann DH.

Am J Med Genet. 2000 May 15;92(2):132-5.

PMID:
10797438
9.

Plexiform neurofibromas in NF1: toward biologic-based therapy.

Packer RJ, Gutmann DH, Rubenstein A, Viskochil D, Zimmerman RA, Vezina G, Small J, Korf B.

Neurology. 2002 May 28;58(10):1461-70. Review.

PMID:
12041525
10.

Response of NF1-related plexiform neurofibroma to high-dose carboplatin.

Hummel T, Anyane-Yeboa A, Mo J, Towbin A, Weiss B.

Pediatr Blood Cancer. 2011 Mar;56(3):488-90. doi: 10.1002/pbc.22827. Epub 2010 Nov 11.

PMID:
21225936
11.

Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial.

Robertson KA, Nalepa G, Yang FC, Bowers DC, Ho CY, Hutchins GD, Croop JM, Vik TA, Denne SC, Parada LF, Hingtgen CM, Walsh LE, Yu M, Pradhan KR, Edwards-Brown MK, Cohen MD, Fletcher JW, Travers JB, Staser KW, Lee MW, Sherman MR, Davis CJ, Miller LC, Ingram DA, Clapp DW.

Lancet Oncol. 2012 Dec;13(12):1218-24. doi: 10.1016/S1470-2045(12)70414-X. Epub 2012 Oct 23.

PMID:
23099009
12.

Association between benign and malignant peripheral nerve sheath tumors in NF1.

Tucker T, Wolkenstein P, Revuz J, Zeller J, Friedman JM.

Neurology. 2005 Jul 26;65(2):205-11.

PMID:
16043787
13.

Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.

Kim A, Dombi E, Tepas K, Fox E, Martin S, Wolters P, Balis FM, Jayaprakash N, Turkbey B, Muradyan N, Choyke PL, Reddy A, Korf B, Widemann BC.

Pediatr Blood Cancer. 2013 Mar;60(3):396-401. doi: 10.1002/pbc.24281. Epub 2012 Sep 7.

PMID:
22961690
15.

Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors.

Endo M, Yamamoto H, Setsu N, Kohashi K, Takahashi Y, Ishii T, Iida K, Matsumoto Y, Hakozaki M, Aoki M, Iwasaki H, Dobashi Y, Nishiyama K, Iwamoto Y, Oda Y.

Clin Cancer Res. 2013 Jan 15;19(2):450-61. doi: 10.1158/1078-0432.CCR-12-1067. Epub 2012 Dec 3.

16.

Longitudinal study of neurofibromatosis 1 associated plexiform neurofibromas.

Tucker T, Friedman JM, Friedrich RE, Wenzel R, Fünsterer C, Mautner VF.

J Med Genet. 2009 Feb;46(2):81-5. doi: 10.1136/jmg.2008.061051. Epub 2008 Oct 17.

PMID:
18930997
17.

MRI growth patterns of plexiform neurofibromas in patients with neurofibromatosis type 1.

Mautner VF, Hartmann M, Kluwe L, Friedrich RE, Fünsterer C.

Neuroradiology. 2006 Mar;48(3):160-5. Epub 2006 Jan 24.

PMID:
16432718
18.

Chromosome 17 loss-of-heterozygosity studies in benign and malignant tumors in neurofibromatosis type 1.

Rasmussen SA, Overman J, Thomson SA, Colman SD, Abernathy CR, Trimpert RE, Moose R, Virdi G, Roux K, Bauer M, Rojiani AM, Maria BL, Muir D, Wallace MR.

Genes Chromosomes Cancer. 2000 Aug;28(4):425-31.

PMID:
10862051
19.

Impact of neurofibromatosis 1 upon quality of life in childhood: a cross-sectional study of 79 cases.

Wolkenstein P, Rodriguez D, Ferkal S, Gravier H, Buret V, Algans N, Simeoni MC, Bastuji-Garin S.

Br J Dermatol. 2009 Apr;160(4):844-8. doi: 10.1111/j.1365-2133.2008.08949.x. Epub 2008 Dec 5.

PMID:
19067713
20.

Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1.

Mautner VF, Asuagbor FA, Dombi E, Fünsterer C, Kluwe L, Wenzel R, Widemann BC, Friedman JM.

Neuro Oncol. 2008 Aug;10(4):593-8. doi: 10.1215/15228517-2008-011. Epub 2008 Jun 17.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk